非小细胞肺癌；新辅助化疗；个体化治疗；基因表达；液相芯片

Abstract:

Objective：To discuss the efforts towards personalizing delivery of care based on the mRNA expression levels of ERCC1，BRCA1，TYMS，RRM1 and TUBB3 by choosing neoadjuvant chemotherapy for 30 ⅢA-N2 non-small-cell lung cancer（NSCLC） pa－tients. Methods：Postoperative samples from 30 ⅢA-N2 NSCLC patients treated with neoadjuvant chemotherapy were analyzed. mRNA expressions of ERCC1，BRCA1，TYMS，RRM1 and TUBB3 were detected by using branched DNA-liquidchip technology（bDNA-LCT）. Results：The total expressions of 5 genotypes from low to high were detected. Correlations were observed between most of these gene expression levels（P<0.05）. All patients were treated with platinum-based neoadjuvant chemo-therapy. ERCC1 and TUBB3 mRNA expressions were associated with the efficacy of neoadjuvant chemotherapy（P<0.05）；lower expression can predict better response. Among these 24 patients treated with antimicrotubules/platinum based chemotherapy，the mRNA expression levels of RRM1 and TUBB3 could be used to predict the treatment outcomes of chemotherapy（P<0.05）. Conclusion：A clear correlation exists between many genes mRNA expression in NSCLC. The mRNA expression levels of many genes could be detected as predictors of the response to neoadjuvant chemotherapy.